BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 2020;29:623-32. [PMID: 32552182 DOI: 10.1080/13543784.2020.1763302] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Reference Citation Analysis]
2 Guan B, Tong J, Hao H, Yang Z, Chen K, Xu H, Wang A. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. Acta Pharmaceutica Sinica B 2021. [DOI: 10.1016/j.apsb.2021.12.011] [Reference Citation Analysis]
3 Wang Y, Crittenden DB, Eng C, Zhang Q, Guo P, Chung D, Fenaux M, Klucher K, Jones C, Jin F, Quirk E, Charlton MR. Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers. Clin Pharmacol Drug Dev 2021. [PMID: 34302449 DOI: 10.1002/cpdd.960] [Reference Citation Analysis]
4 Jiang L, Zhang H, Xiao D, Wei H, Chen Y. Farnesoid X receptor (FXR): Structures and ligands. Comput Struct Biotechnol J 2021;19:2148-59. [PMID: 33995909 DOI: 10.1016/j.csbj.2021.04.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sohail MI, Dönmez-Cakil Y, Szöllősi D, Stockner T, Chiba P. The Bile Salt Export Pump: Molecular Structure, Study Models and Small-Molecule Drugs for the Treatment of Inherited BSEP Deficiencies. Int J Mol Sci 2021;22:E784. [PMID: 33466755 DOI: 10.3390/ijms22020784] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Rohilla S, Awasthi A, Kaur S, Puria R. Evolutionary conservation of long non-coding RNAs in non-alcoholic fatty liver disease. Life Sci 2021;264:118560. [PMID: 33045214 DOI: 10.1016/j.lfs.2020.118560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Fiorucci S, Distrutti E, Carino A, Zampella A, Biagioli M. Bile acids and their receptors in metabolic disorders. Prog Lipid Res 2021;82:101094. [PMID: 33636214 DOI: 10.1016/j.plipres.2021.101094] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
8 Fiorucci S, Distrutti E. Linking liver metabolic and vascular disease via bile acid signaling. Trends Mol Med 2022;28:51-66. [PMID: 34815180 DOI: 10.1016/j.molmed.2021.10.005] [Reference Citation Analysis]
9 Xue R, Su L, Lai S, Wang Y, Zhao D, Fan J, Chen W, Hylemon PB, Zhou H. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease. Cells 2021;10:2806. [PMID: 34831031 DOI: 10.3390/cells10112806] [Reference Citation Analysis]
10 Fiorucci S, Biagioli M, Baldoni M, Ricci P, Sepe V, Zampella A, Distrutti E. The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. Expert Opin Drug Discov 2021;:1-16. [PMID: 33849361 DOI: 10.1080/17460441.2021.1916465] [Reference Citation Analysis]
11 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Reference Citation Analysis]
12 Jiang L, Xiao D, Li Y, Dai S, Qu L, Chen X, Guo M, Wei H, Chen Y. Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor. Biochem Biophys Res Commun 2021;534:1047-52. [PMID: 33121679 DOI: 10.1016/j.bbrc.2020.10.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Marchianò S, Biagioli M, Roselli R, Zampella A, Di Giorgio C, Bordoni M, Bellini R, Morretta E, Monti MC, Distrutti E, Fiorucci S. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. FASEB J 2022;36:e22060. [PMID: 34862975 DOI: 10.1096/fj.202101397R] [Reference Citation Analysis]